Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9150 + acalabrutinib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Oral
01
Overview
AZD9150 + acalabrutinib is an investigational combination therapy being studied for relapsed/refractory aggressive Non-Hodgkin's lymphoma. AZD9150 is an antisense oligonucleotide inhibitor of the transcription factor signal transducer and activator of transcription 3 (STAT3), which plays a role in cancer cell survival and proliferation. Acalabrutinib is a selective small molecule inhibitor of the Bruton tyrosine kinase (BTK) and is marketed as CALQUENCE. The combination aims to inhibit two critical oncogenic pathways: STAT3 signaling and BTK-mediated B-cell receptor signaling. AZD9150 is administered intravenously, while acalabrutinib is given orally. Primary indications under investigation are relapsed/refractory aggressive Non-Hodgkin's lymphoma, with clinical trials exploring this regimen's safety and efficacy[1][3][5][6].
- Brand names
- CALQUENCE
- Other names
- STAT3 inhibitorSTAT-3 inhibitorSTAT 3 inhibitoracalabrutinibdanvatirsen
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on AZD9150 + acalabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9150 + acalabrutinib.